Teva flogs animal health business to Bayer for $145m
This article was originally published in Scrip
Teva has sold its US-based animal health business to Bayer for $145 million in line with its strategy to focus solely on its core human health business. Itzhak Krinsky, Teva’s group executive vice-president and head of business development, said, “As part of our overall strategy to refine our global footprint, we will continue to leverage our product portfolio and R&D efforts while selling or out-licensing assets that no longer fit within the scope of our business." The deal includes $60 million upfront and $85 million in manufacturing and sales milestones, and is expected to close in 2013. Bayer will integrate the assets into its companion and food animal products line.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.